
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Benitec Biopharma Ltd ADR (BNTC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BNTC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $25.71
1 Year Target Price $25.71
4 | Strong Buy |
3 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.31% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 332.33M USD | Price to earnings Ratio - | 1Y Target Price 25.71 |
Price to earnings Ratio - | 1Y Target Price 25.71 | ||
Volume (30-day avg) 7 | Beta 0.4 | 52 Weeks Range 8.06 - 17.15 | Updated Date 08/15/2025 |
52 Weeks Range 8.06 - 17.15 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.34% | Return on Equity (TTM) -48.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 229706937 | Price to Sales(TTM) 2770.13 |
Enterprise Value 229706937 | Price to Sales(TTM) 2770.13 | ||
Enterprise Value to Revenue 10457.68 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 26250500 | Shares Floating 12567143 |
Shares Outstanding 26250500 | Shares Floating 12567143 | ||
Percent Insiders 3.12 | Percent Institutions 90.98 |
Upturn AI SWOT
Benitec Biopharma Ltd ADR

Company Overview
History and Background
Benitec Biopharma Ltd (BNTC) is a biotechnology company focused on the development of novel genetic medicines based on its proprietary DNA-directed RNA interference ('ddRNAi') platform. Founded in 1997, Benitec has aimed to develop innovative therapeutics for chronic and life-threatening human diseases.
Core Business Areas
- Gene Therapy: Focuses on developing ddRNAi-based therapies for various diseases, including Oculopharyngeal Muscular Dystrophy (OPMD) and other genetic disorders.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and drug development. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- BB-301 (for OPMD): BB-301 is Benitec's lead product candidate, a gene therapy treatment for OPMD. It uses ddRNAi to reduce expression of the mutated PABPN1 gene. The market for OPMD treatments is currently underserved. Competitors are generally other companies pursuing gene therapy or alternative treatments for OPMD.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing regulatory approvals. There's substantial investment and competition in this space.
Positioning
Benitec is positioned as a specialized gene therapy company with a focus on ddRNAi technology. Its competitive advantage lies in the potential of ddRNAi to provide a durable and specific therapeutic effect.
Total Addressable Market (TAM)
The TAM for OPMD and other genetic disorders targeted by Benitec's pipeline is substantial. Benitec's position depends on clinical success and market access.
Upturn SWOT Analysis
Strengths
- Proprietary ddRNAi technology
- Lead product candidate in clinical development (BB-301)
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
Opportunities
- Positive clinical trial data
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from other gene therapy companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PTCT
- SRPT
- CRSP
Competitive Landscape
Benitec faces competition from larger, more established biotechnology and pharmaceutical companies. Its competitive advantage lies in its ddRNAi technology, but it needs to secure funding and demonstrate clinical efficacy to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancing BB-301 through clinical development.
Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approvals for BB-301 and other pipeline candidates.
Recent Initiatives: Recent initiatives include enrollment in clinical trials for BB-301 and exploration of partnerships.
Summary
Benitec Biopharma is a high-risk, high-reward clinical-stage biotechnology company. Its ddRNAi technology holds promise, but its success hinges on clinical trial outcomes and funding. The company faces significant competition and financial challenges. Positive data from BB-301's clinical trials is essential for future growth and shareholder value. Future growth will also be influenced by any potential collaborations or partnerships formed with larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Information is based on publicly available data and may be subject to change. Investing in clinical-stage biotechnology companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Benitec Biopharma Ltd ADR
Exchange NASDAQ | Headquaters Hayward, CA, United States | ||
IPO Launch date 2015-08-18 | Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://benitec.com |
Full time employees 16 | Website https://benitec.com |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.